ECRIN's vision is a society where all decisions in medical practice are made based on sound scientific evidence from high-quality clinical research. To achieve this vision, ECRIN supports the conduct of independent, multinational clinical trials. By managing and supporting clinical trials across borders, connecting networks, and advising and implementing policy, ECRIN advances knowledge flow, competitiveness and integration in European clinical research.
Independent clinical trials can provide immediate return on investment, as in the 6S trial, which examined the approved treatment of patients with severe sepsis with intravenous hydroxyethyl starch. The trial showed that this treatment worsened patient outcomes and these results led to changes in clinical practice.
Independent trials may also be investments in future innovative healthcare, such as the ChildInnovac trial, which may lead to development of an innovative recombinant transnasal pertussis vaccine and also contributes as a proof-of-concept study for vaccine administration via the respiratory tract. What is the impact of the 6S trial on clinical practice and patient outcomes?
This prompt doesn't seem malicious.